Drug recall · July 1, 2026
DULOXETINE D/R recall
Why: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
- Lots / codes
Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027.
- Quantity
- 263 Bottles
- Company
- Direct Rx, Dawsonville, GA
- Distribution
- U.S. Nationwide
- Initiated
- June 22, 2026 · Voluntary: Firm initiated
- Classified
- June 23, 2026
- Reported
- July 1, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Duloxetine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.